Scarica l'app Stockscreener
113.92
0.72%
-0.83
Dopo l'orario di chiusura:
114.31
0.39
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead granted EU nod for twice-yearly HIV PrEP therapy - MSN
Analyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why - MSN
US judge recuses herself from black-market drug case over Gilead stock purchases - Reuters
Stock Analysis | Gilead Sciences OutlookTechnical Neutrality and Mixed Analyst Signals - AInvest
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU - sharewise.com
Gilead's Lenacapavir Approved in EU for HIV Prevention - AInvest
Gilead Sciences’ HIV PrEP Injectable Approved by European Commission - PharmTech
Gilead Notches Another Win For 99.9% Effective HIV Drug - Investor's Business Daily
Visual trend scoring systems applied to Gilead Sciences Inc.Weekly Investment Report & Weekly Watchlist for Hot Stocks - Newser
Gilead's Lenacapavir Approved in Europe for HIV Prevention - AInvest
Gilead Sciences' Yeytuo: A Paradigm Shift in HIV Prevention and a Catalyst for Long-Term Profitability - AInvest
EU approves Gilead's new injection for preventing HIV - Reuters
Gilead Granted Marketing Authorization for Twice-Yearly HIV PrEP Shot in Europe - Contract Pharma
Gilead twice-yearly HIV PrEP drug OKed in EU (GILD:NASDAQ) - Seeking Alpha
Statistical indicators supporting Gilead Sciences Inc.’s strengthQuarterly Portfolio Review & Reliable Intraday Trade Plans - Newser
Gilead Sciences' Yeztugo: A Paradigm Shift in HIV Prevention and Investment Potential - AInvest
Gilead Sciences says European Commission authorizes twice-yearly Yeytuo for HIV prevention - MarketScreener
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention - Business Wire
Will Gilead Sciences Inc. stock recover after recent dropJuly 2025 Review & Weekly High Potential Stock Alerts - Newser
Will Gilead Sciences Inc. bounce back from current supportMarket Trend Review & Low Drawdown Trading Techniques - Newser
Gilead Sciences Advances in NSCLC Treatment: Key Study Update - TipRanks
Gilead Sciences Redux: Why I'm Once Again Targeting This Big Pharma - TheStreet Pro
Will Gilead Sciences Inc. rebound enough to break evenLayoff News & Free Weekly Chart Analysis and Trade Guides - Newser
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish - MSN
Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study - TipRanks
Gilead Sciences’ New HIV Treatment Study: A Potential Game-Changer? - TipRanks
Gilead Sciences Stock (GILD) Turns Negative As CVS Says No To HIV Prevention Drug - TipRanks
Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius - BioPharma Dive
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy - Benzinga
Why Gilead Sciences (GILD) Shares Are Sliding Today - Yahoo Finance
Coty, Gilead Sciences, Rent the Runway: Trending tickers - Yahoo Finance
Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million - statnews.com
Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists - Reuters
Gilead unit to acquire cell therapy developer Interius for $350 million - Reuters
Gilead Falls as CVS Hasn’t Yet Added PrEP HIV Shot to Drug Plans - Bloomberg.com
Gilead Sciences to Buy Interius BioTherapeutics for $350 Million - MarketScreener
Why Is Gilead Sciences Stock Falling Thursday?CVS Health (NYSE:CVS), Gilead Sciences (NASDAQ:GILD) - Benzinga
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire
Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition - MedCity News
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave (NASDAQ:GILD) - Seeking Alpha
Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists By Reuters - Investing.com
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
We are positive on Gilead Sciences' base business growth: Meacham - BNN Bloomberg
Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent
Insider Selling at Gilead Sciences: A Signal of Liquidity or a Cautionary Tale? - AInvest
Mizuho Securities Keeps Buy Rating on Gilead Sciences with $131 Target - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Gilead Sciences CCO Mercier sells $3.3m in shares - Investing.com
Gilead Sciences Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Outlook & Community Verified Swing Trade Signals - beatles.ru
Gilead Sciences CFO sells $296k in shares - Investing.com
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? - Nasdaq
Sure, Biogen (BIIB) Has Been on a Hot Streak Recently But My Bet’s on Gilead Sciences (GILD) - Money Morning
Argus Adjusts Price Target on Gilead Sciences to $130 From $120 - MarketScreener
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use - PMLiVE
Gilead Sciences stock price target raised to $131 from $117 at Mizuho - Investing.com Canada
Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating - MarketScreener
Gilead Sciences' Outperformance Means Overvalued (NASDAQ:GILD) - Seeking Alpha
Short Covering May Lift Gilead Sciences Inc. in Near TermJuly 2025 Patterns & Weekly High Return Forecasts - metal.it
What makes Gilead Sciences Inc. stock attractive todayJuly 2025 Review & Fast Moving Market Watchlists - thegnnews.com
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences Stock Surges in Trading Volume to 96th Rank Amid 0.55% Drop and Insider Sales - AInvest
Gilead Sciences Appoints New Senior Vice President - The Globe and Mail
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - MSN
Gilead Sciences and the Pricing Strategy of Lenacapavir: Balancing Profit and Public Health in the Fight Against HIV - AInvest
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value - Bloomberg.com
0.60%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):